Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mariko DeWire

Showing results (11-20 of 27) with videos related to

Pageof 3
Sort By:
Pediatric Blood & Cancer|October 21, 2014
Pubertal development and primary ovarian insufficiency in female survivors of embryonal brain tumors following risk-adapted craniospinal irradiation and adjuvant chemotherapyMariko DeWire, Daniel M Green, Charles A Sklar, et al.
Neuro-Oncology|March 25, 2017
The transcription factor Olig2 is important for the biology of diffuse intrinsic pontine gliomasJane L Anderson, Ranjithmenon Muraleedharan, Nicole Oatman, et al.
Journal of Neuro-Oncology|December 3, 2015
A pilot study of bevacizumab-based therapy in patients with newly diagnosed high-grade gliomas and diffuse intrinsic pontine gliomasTrent R Hummel, Ralph Salloum, Rachid Drissi, et al.
Journal of Neuro-Oncology|April 11, 2015
An open-label, two-stage, phase II study of bevacizumab and lapatinib in children with recurrent or refractory ependymoma: a collaborative ependymoma research network study (CERN)Mariko DeWire, Maryam Fouladi, David C Turner, et al.
Acta Neuropathologica Communications|January 6, 2016
Spatial genomic heterogeneity in diffuse intrinsic pontine and midline high-grade glioma: implications for diagnostic biopsy and targeted therapeuticsLindsey M Hoffman, Mariko DeWire, Scott Ryall, et al.
Acta Neuropathologica Communications|February 11, 2016
Erratum: Spatial genomic heterogeneity in diffuse intrinsic pontine and midline high-grade glioma: implications for diagnostic biopsy and targeted therapeuticsLindsey M Hoffman, Mariko DeWire, Scott Ryall, et al.
Pediatric Blood & Cancer|January 6, 2021
A phase I trial of the CDK 4/6 inhibitor palbociclib in pediatric patients with progressive brain tumors: A Pediatric Brain Tumor Consortium study (PBTC-042)David Van Mater, Sridharan Gururangan, Oren Becher, et al.
Journal of Neuro-Oncology|October 9, 2020
A phase I/II study of ribociclib following radiation therapy in children with newly diagnosed diffuse intrinsic pontine glioma (DIPG)Mariko DeWire, Christine Fuller, Trent R Hummel, et al.
Neuro-Oncology|February 11, 2022
Volumetric endpoints in diffuse intrinsic pontine glioma: comparison to cross-sectional measures and outcome correlations in the International DIPG/DMG RegistryMargot A Lazow, Martijn T Nievelstein, Adam Lane, et al.
Acta Neuropathologica Communications|November 1, 2017
Characterizing temporal genomic heterogeneity in pediatric high-grade gliomasRalph Salloum, Melissa K McConechy, Leonie G Mikael, et al.
Pageof 3

Showing results (11-20 of 27) with videos related to

Sort By:
Pageof 3
Pediatric Blood & Cancer|October 21, 2014
Pubertal development and primary ovarian insufficiency in female survivors of embryonal brain tumors following risk-adapted craniospinal irradiation and adjuvant chemotherapyMariko DeWire, Daniel M Green, Charles A Sklar, et al.
Neuro-Oncology|March 25, 2017
The transcription factor Olig2 is important for the biology of diffuse intrinsic pontine gliomasJane L Anderson, Ranjithmenon Muraleedharan, Nicole Oatman, et al.
Journal of Neuro-Oncology|December 3, 2015
A pilot study of bevacizumab-based therapy in patients with newly diagnosed high-grade gliomas and diffuse intrinsic pontine gliomasTrent R Hummel, Ralph Salloum, Rachid Drissi, et al.
Journal of Neuro-Oncology|April 11, 2015
An open-label, two-stage, phase II study of bevacizumab and lapatinib in children with recurrent or refractory ependymoma: a collaborative ependymoma research network study (CERN)Mariko DeWire, Maryam Fouladi, David C Turner, et al.
Acta Neuropathologica Communications|January 6, 2016
Spatial genomic heterogeneity in diffuse intrinsic pontine and midline high-grade glioma: implications for diagnostic biopsy and targeted therapeuticsLindsey M Hoffman, Mariko DeWire, Scott Ryall, et al.
Acta Neuropathologica Communications|February 11, 2016
Erratum: Spatial genomic heterogeneity in diffuse intrinsic pontine and midline high-grade glioma: implications for diagnostic biopsy and targeted therapeuticsLindsey M Hoffman, Mariko DeWire, Scott Ryall, et al.
Pediatric Blood & Cancer|January 6, 2021
A phase I trial of the CDK 4/6 inhibitor palbociclib in pediatric patients with progressive brain tumors: A Pediatric Brain Tumor Consortium study (PBTC-042)David Van Mater, Sridharan Gururangan, Oren Becher, et al.
Journal of Neuro-Oncology|October 9, 2020
A phase I/II study of ribociclib following radiation therapy in children with newly diagnosed diffuse intrinsic pontine glioma (DIPG)Mariko DeWire, Christine Fuller, Trent R Hummel, et al.
Neuro-Oncology|February 11, 2022
Volumetric endpoints in diffuse intrinsic pontine glioma: comparison to cross-sectional measures and outcome correlations in the International DIPG/DMG RegistryMargot A Lazow, Martijn T Nievelstein, Adam Lane, et al.
Acta Neuropathologica Communications|November 1, 2017
Characterizing temporal genomic heterogeneity in pediatric high-grade gliomasRalph Salloum, Melissa K McConechy, Leonie G Mikael, et al.
Pageof 3